Infectious Disease

Pulmonary Tuberculosis

97

Pipeline Programs↗

14

Active Trials↗

30

Companies Involved↗

Pulmonary Tuberculosis is a moderately active landscape with 97 programs across 30 companies. The most active players are Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Boehringer Ingelheim, Johnson & Johnson. 12 therapies are approved with 15 more in late-stage development.

Intelligence

Pipeline Metrics

Competitive Density

70/100

Pipeline Velocity

22/100

Mech. Concentration

19/100

Completion Rate

96/100

Attrition Rate

3/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved

Phase 3

Phase 2

Phase 1

Preclinical

Key Players

Top Companies

Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.

1 program

Boehringer Ingelheim

2 programs

Johnson & Johnson

1 program

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

1 program

Bayer

1 program

EMD Serono

1 program

Pipeline

Programs by Phase

Preclinical17

Bupropion

Glaxo Dba Glaxosmithkline

Delamanid

Otsuka

Interferon Gamma-1b

Horizon Therapeutics Ireland DAC

Dexamethasone Sodium Phosphate

Quince Therapeutics S.p.A.

Clofazimine

Novartis

Phase 12

Levofloxacin

Wim Janssens

Pyridoxine Hydrochloride

National Institute of Allergy and Infectious Diseases (NIAID)

Phase 251

Rifampin

Sanofi

Pyrazinamide

Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections

Pretomanid

Pfizer's Upjohn has merged with Mylan to form Viatris Inc.

Moxifloxacin

Bayer

Linezolid

Pfizer

Phase 315

Cholecalciferol

Hyundai Pharmaceutical Co., LTD.

Bedaquiline

Wim Janssens

Micronutrient With Zinc

All India Institute of Medical Sciences

Zinc

American Regent, Inc.

L-Arginine

Mario Negri Institute for Pharmacological Research

Approved12

Amoxicillin

Global Antibiotics Research and Development Partnership

Ethambutol

VA Greater Los Angeles Healthcare System

Rifapentine

Sanofi

Ergocalciferol

Alnylam Pharmaceuticals

Dexamethasone

Aspen Global Incorporated

Analysis

Modality Breakdown

96%

Small molecule

120 of 125 classified programs — the dominant modality here.

Small molecule leads; the ring shows all 125 classified programs, each share of the total. Modality classified for 98% of 130 pipeline programs.

Analysis

Trial Status

79

clinical trials

Completed46 · 58%

Unknown status16 · 20%

Recruiting10 · 13%

Active, not recruiting2 · 3%

Not yet recruiting2 · 3%

Terminated2 · 3%

Other1 · 1%

Clinical Trials

Trial Activity

79 trials

Efficacy Safety BaiDiZiYin ShenQiYiFei Adjunctive Treatments Pulmonary Tuberculosis

Recruiting·—·Phase 4·NCT06403943·292 enrolled

A Study of Quabodepistat-containing Regimens for the Treatment of Drug-resistant Pulmonary Tuberculosis

Recruiting· Otsuka logo

Otsuka·Phase 3·NCT07209761·532 enrolled

A Pragmatic Trial With Optimized Dose of Rifampicin and Moxifloxacin for the Treatment of Drug Susceptible Pulmonary Tuberculosis

Recruiting·—·Phase 3·NCT05575518·414 enrolled

Doxycycline Host-directed Therapy to Improve Lung Function and Decrease Tissue Destruction in Pulmonary Tuberculosis

Recruiting·NNational University Hospital, Singapore·Phase 3·NCT05473520·150 enrolled

ATORvastatin in Pulmonary TUBerculosis

Recruiting·OObafemi Awolowo University Teaching Hospital·Phase 2·NCT06199921·440 enrolled

ATORvastatin in Pulmonary TUBerculosis: a POPulation PharmacoKinetics -PharmacoDynamics Sub-study (ATORTUB popPK-PD)

Recruiting·OObafemi Awolowo University Teaching Hospital·Phase 2·NCT07303699·80 enrolled

A Phase III Study of Oral Sudapyridine (WX-081) Tablets in Rifampicin-Resistant Pulmonary Tuberculosis Patients

Recruiting·SShanghai Jiatan Pharmatech Co., Ltd·Phase 3·NCT05824871·450 enrolled

A Phase 2, Open-Label, Multi-Group, Controlled, Randomized Trial of the Safety, Bactericidal Activity, and Pharmacokinetics of TBD09 in Combination With Other Active Agents in Adults With Drug-Sensitive Pulmonary Tuberculosis

Recruiting·GGates Medical Research Institute·Phase 2·NCT07525427·150 enrolled

A Phase 2, Open-label, Randomized Controlled Trial to Assess the Safety, Bactericidal Activity, and Pharmacokinetics of Nicotinamide in Combination With Bedaquiline, Pretomanid, and Linezolid in Adults With Drug-susceptible Pulmonary Tuberculosis

Recruiting·GGates Medical Research Institute·Phase 2·NCT07517445·165 enrolled

A Phase 2 Randomized, Adaptive, Dose-Ranging, Open-Label Trial of Novel Regimens for the Treatment of Pulmonary Tuberculosis

Recruiting·National Institute of Allergy and Infectious Diseases (NIAID)·Phase 2·NCT06192160·315 enrolled

Short-course Regimens for the Treatment of Pulmonary Tuberculosis

Active, not recruiting·Centers for Disease Control and Prevention·Phase 2/3·NCT05766267·288 enrolled

I-FALMIN Albumin Supplement for Patients With Pulmonary Tuberculosis

Active, not recruiting·HHasanuddin University·N/A·NCT07186478·112 enrolled

Treatment Shortening of Drug-Sensitive Pulmonary Tuberculosis Using High Dose Rifampicin (Hi-DoRi-3)

Not yet recruiting·SSeoul National University Hospital·Phase 3·NCT04485156·926 enrolled

AIPH-TB: AI-Optimised Pyrazinamide-Hydroxychloroquine vs Standard RIPE for Drug-Sensitive Pulmonary Tuberculosis - A Phase II RCT

Not yet recruiting·Ministry of Health, Saudi Arabia·Phase 2·NCT07467252·200 enrolled

A Phase 2 to Evaluate the Efficacy, Safety and Tolerability of Combinations of Bedaquiline, Moxifloxacin, PA-824 and Pyrazinamide in Adult Subjects With Drug-Sensitive or Multi Drug-Resistant Pulmonary Tuberculosis.

Completed·GGlobal Alliance for TB Drug Development·Phase 2·NCT02193776·240 enrolled

Page 1 of 6

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)